Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.

Khan S, Khan S, Imran M, Pillai KK, Akhtar M, Najmi AK.

Expert Opin Ther Targets. 2013 Jun;17(6):627-39. doi: 10.1517/14728222.2013.764991. Epub 2013 Jan 28. Review.

PMID:
23356568
2.
3.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

4.

Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.

Halimi S, Raccah D, Schweizer A, Dejager S.

Curr Med Res Opin. 2010 Jul;26(7):1647-56. doi: 10.1185/03007995.2010.485881. Review.

PMID:
20441397
6.

The scientific evidence: vildagliptin and the benefits of islet enhancement.

Mathieu C.

Diabetes Obes Metab. 2009 May;11 Suppl 2:9-17. doi: 10.1111/j.1463-1326.2008.01033.x. Review.

PMID:
19385979
7.

Vildagliptin in clinical practice: a review of literature.

Banerjee M, Younis N, Soran H.

Expert Opin Pharmacother. 2009 Nov;10(16):2745-57. doi: 10.1517/14656560903302265. Review.

PMID:
19874253
8.

The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.

Panina G.

Diabetes Obes Metab. 2007 Sep;9 Suppl 1:32-9. Review.

PMID:
17877545
9.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
10.

Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.

Croxtall JD, Keam SJ.

Drugs. 2008;68(16):2387-409. doi: 10.2165/0003495-200868160-00009. Review.

PMID:
18973400
11.

The role of vildagliptin in the management of type 2 diabetes mellitus.

Kleppinger EL, Helms K.

Ann Pharmacother. 2007 May;41(5):824-32. Epub 2007 Apr 24. Review.

PMID:
17456545
12.

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.

Guarino E, Nigi L, Patti A, Fondelli C, Dotta F.

Expert Opin Pharmacother. 2012 Jun;13(9):1377-84. doi: 10.1517/14656566.2012.667078. Epub 2012 Mar 7. Review.

PMID:
22397507
13.
14.

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.

Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE.

Diabetes Obes Metab. 2011 Sep;13(9):775-83. doi: 10.1111/j.1463-1326.2011.01414.x. Review.

PMID:
21507182
15.

Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.

Rosenstock J, Fitchet M.

Int J Clin Pract Suppl. 2008 Mar;(159):15-23. doi: 10.1111/j.1742-1241.2007.01692.x. Review.

PMID:
18269437
16.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006739. doi: 10.1002/14651858.CD006739.pub2. Review.

PMID:
18425967
17.

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.

Halimi S, Schweizer A, Minic B, Foley J, Dejager S.

Vasc Health Risk Manag. 2008;4(3):481-92. Review.

18.

Vildagliptin in the treatment of type 2 diabetes mellitus.

Stamataros G, Schneider SH.

Expert Opin Pharmacother. 2011 Aug;12(12):1967-73. doi: 10.1517/14656566.2011.593508. Epub 2011 Jun 17. Review.

PMID:
21679097
19.

New treatments for type 2 diabetes--the DPP4 inhibitors.

Gadsby R.

Prim Care Diabetes. 2007 Dec;1(4):209-11. doi: 10.1016/j.pcd.2007.10.004. Epub 2007 Dec 3. Review.

PMID:
18632049
20.

Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.

Del Prato S.

Int J Clin Pract Suppl. 2007 Aug;(154):38-48. Review.

PMID:
17593276

Supplemental Content

Support Center